Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)
|
September 7, 2023
Antibody Batch Cloning
Rico Ballmann, Kai-Thomas Schneider, Kristian Daniel Ralph Roth, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
September 7, 2023
Biomarker Discovery by ORFeome Phage Display
Philip Alexander Heine, Rico Ballmann, Praveen Thevarajah, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
September 7, 2023
Antibody Selection via Phage Display in Microtiter Plates
Stephan Steinke, Kristian Daniel Ralph Roth, Maximilian Ruschig, et al.
Viruses
|
June 24, 2022
ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein
Rico Ballmann, Sven-Kevin Hotop, Federico Bertoglio, et al.
Emerging Microbes & Infections
|
March 23, 2022
Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2
Sven-Kevin Hotop, Susanne Reimering, Aditya Shekhar, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
September 7, 2023
Mapping Epitopes by Phage Display
Stephan Steinke, Kristian Daniel Ralph Roth, Ruben Englick, et al.
Viruses
|
October 27, 2022
Baculovirus-Free SARS-CoV-2 Virus-like Particle Production in Insect Cells for Rapid Neutralization Assessment
Marcel Jaron, Michael Lehky, Marta Zarà, et al.
Frontiers in Cellular and Infection Microbiology
|
July 26, 2021
Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
Kristian Daniel Ralph Roth, Esther Veronika Wenzel, Maximilian Ruschig, et al.
Nature Communications
|
March 12, 2021
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
Federico Bertoglio, Doris Meier, Nora Langreder, et al.
Cell Reports
|
July 17, 2021
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
Federico Bertoglio, Viola Fühner, Maximilian Ruschig, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Methods in Molecular Biology (Clifton, N.J.)
|
September 7, 2023
Antibody Batch Cloning
Rico Ballmann, Kai-Thomas Schneider, Kristian Daniel Ralph Roth, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
September 7, 2023
Biomarker Discovery by ORFeome Phage Display
Philip Alexander Heine, Rico Ballmann, Praveen Thevarajah, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
September 7, 2023
Antibody Selection via Phage Display in Microtiter Plates
Stephan Steinke, Kristian Daniel Ralph Roth, Maximilian Ruschig, et al.
Viruses
|
June 24, 2022
ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein
Rico Ballmann, Sven-Kevin Hotop, Federico Bertoglio, et al.
Emerging Microbes & Infections
|
March 23, 2022
Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2
Sven-Kevin Hotop, Susanne Reimering, Aditya Shekhar, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
September 7, 2023
Mapping Epitopes by Phage Display
Stephan Steinke, Kristian Daniel Ralph Roth, Ruben Englick, et al.
Viruses
|
October 27, 2022
Baculovirus-Free SARS-CoV-2 Virus-like Particle Production in Insect Cells for Rapid Neutralization Assessment
Marcel Jaron, Michael Lehky, Marta Zarà, et al.
Frontiers in Cellular and Infection Microbiology
|
July 26, 2021
Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
Kristian Daniel Ralph Roth, Esther Veronika Wenzel, Maximilian Ruschig, et al.
Nature Communications
|
March 12, 2021
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
Federico Bertoglio, Doris Meier, Nora Langreder, et al.
Cell Reports
|
July 17, 2021
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
Federico Bertoglio, Viola Fühner, Maximilian Ruschig, et al.
Page
of 1